✦ LIBER ✦

6003 ORAL Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL)

✍ Scribed by Crump, M.; Coiffier, B.; Jacobsen, E.D.; Sun, L.; Ricker, J.L.; Xie, H.; Frankel, S.R.; Randolph, S.S.; Cheson, B.D.

Book ID: 123564678
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 62 KB
Volume: 5
Category: Article
ISSN: 1359-6349
DOI: 10.1016/S1359-6349(07)71294-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

FDG-PET/CT for the Evaluation of Respons

FDG-PET/CT for the Evaluation of Response to Therapy of Cutaneous T-cell Lymphoma to Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) in a Phase II Trial

✍ Phillip H. Kuo; Kacie R. Carlson; Inger Christensen; Michael Girardi; Peter W. H 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 395 KB

Oral lenalidomide with rituximab in rela

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

✍ Wang, M; Fowler, N; Wagner-Bartak, N; Feng, L; Romaguera, J; Neelapu, S S; Hagem 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 817 KB

Oral lenalidomide with rituximab in rela

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

✍ Wang, M; Fowler, N; Wagner-Bartak, N; Feng, L; Romaguera, J; Neelapu, S S; Hagem 📂 Article 📅 2013 🏛 Nature Publishing Group 🌐 English ⚖ 817 KB

Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell lymphoma (TL) and grade 3 follicular lymphoma (FLG3) is unknown. In this phase II trial, 45 patients with relapsed or refrac